Research progress of breast cancer with low HER2 expression

doi:10.3760/cma.j.cn371439-20220609-00099

Abstract

Abstract:

Breast cancer with low expression of human epidermal growth factor receptor 2 （HER2） has unique biological behaviors. Compared with HER2-zero breast cancer, there are significant differences in molecular subtype and gene expression between the two categories of breast cancer. Novel antibody-drug conjugates represented by T-DXd provide a new treatment option for patients with HER2-low breast cancer, and relevant clinical trials are continuing. At present, the relationship between HER2-low status and prognosis of breast cancer patients remains controversial. In-depth research into HER2-low breast cancer will help further improve clinical outcomes for this population.

Key words: Breast neoplasms, Prognosis, Therapeutics, Low expression of human epidermal growth factor receptor 2

Xu Hangcheng, Wu Yun, Wang Jiayu. Research progress of breast cancer with low HER2 expression[J]. Journal of International Oncology, 2022, 49(9): 513-516.

References 34

[1]	Piccart M, Procter M, Fumagalli D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' follow-up[J]. J Clin Oncol, 2021, 39(13): 1448-1457. DOI: 10.1200/JCO.20.01204. doi: 10.1200/JCO.20.01204 pmid: 33539215
[2]	Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (Cleopatra): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(4): 519-530. DOI: 10.1016/S1470-2045(19)30863-0. doi: S1470-2045(19)30863-0 pmid: 32171426
[3]	Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962. DOI: 10.1200/JCO.19.02488. doi: 10.1200/JCO.19.02488 pmid: 32330069
[4]	Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ⅰb study[J]. J Clin Oncol, 2020, 38(17): 1887-1896. DOI: 10.1200/JCO.19.02318. doi: 10.1200/JCO.19.02318
[5]	Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer[J]. NPJ Breast Cancer, 2021, 7(1): 1. DOI: 10.1038/s41523-020-00208-2. doi: 10.1038/s41523-020-00208-2
[6]	Jacot W, Maran-Gonzalez A, Massol O, et al. Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers[J]. Cancers (Basel), 2021, 13(23): 6059. DOI: 10.3390/cancers13236059. doi: 10.3390/cancers13236059
[7]	Mutai R, Barkan T, Moore A, et al. Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer[J]. Breast, 2021, 60: 62-69. DOI: 10.1016/j.breast.2021.08.016. doi: 10.1016/j.breast.2021.08.016 pmid: 34481367
[8]	Zhang H, Katerji H, Turner BM, et al. HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles[J]. Mod Pathol, 2022, 35(8): 1075-1082. DOI: 10.1038/s41379-022-01019-5. doi: 10.1038/s41379-022-01019-5
[9]	Guven DC, Kaya MB, Fedai B, et al. HER2-low breast cancer could be associated with an increased risk of brain metastasis[J]. Int J Clin Oncol, 2022, 27(2): 332-339. DOI: 10.1007/s10147-021-02049-w. doi: 10.1007/s10147-021-02049-w
[10]	Eggemann H, Ignatov T, Burger E, et al. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer[J]. Endocr Relat Cancer, 2015, 22(5): 725-733. DOI: 10.1530/ERC-15-0335. doi: 10.1530/ERC-15-0335
[11]	Rossi V, Sarotto I, Maggiorotto F, et al. Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer[J]. Oncologist, 2012, 17(11): 1418-1425. DOI: 10.1634/theoncologist.2012-0194. doi: 10.1634/theoncologist.2012-0194 pmid: 22951668
[12]	Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials[J]. Lancet Oncol, 2021, 22(8): 1151-1161. DOI: 10.1016/S1470-2045(21)00301-6. doi: 10.1016/S1470-2045(21)00301-6 pmid: 34252375
[13]	Rosso C, Voutsadakis IA. Characteristics, clinical differences and outcomes of breast cancer patients with negative or low HER2 expression[J]. Clin Breast Cancer, 2022, 22(4): 391-397. DOI: 10.1016/j.clbc.2022.02.008. doi: 10.1016/j.clbc.2022.02.008 pmid: 35337735
[14]	Horisawa N, Adachi Y, Takatsuka D, et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status[J]. Breast Cancer, 2022, 29(2): 234-241. DOI: 10.1007/s12282-021-01303-3. doi: 10.1007/s12282-021-01303-3
[15]	de Moura Leite L, Cesca MG, Tavares MC, et al. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer[J]. Breast Cancer Res Treat, 2021, 190(1): 155-163. DOI: 10.1007/s10549-021-06365-7. doi: 10.1007/s10549-021-06365-7
[16]	Xu H, Han Y, Wu Y, et al. Clinicopathological characteristics and prognosis of HER2-low early-stage breast cancer: a single-institution experience[J]. Front Oncol, 2022, 12: 906011. DOI: 10.3389/fonc.2022.906011. doi: 10.3389/fonc.2022.906011
[17]	Agostinetto E, Rediti M, Fimereli D, et al. HER2-low breast cancer: molecular characteristics and prognosis[J]. Cancers (Basel), 2021, 13(11): 2824. DOI: 10.3390/cancers13112824. doi: 10.3390/cancers13112824
[18]	Zhang G, Ren C, Li C, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status[J]. BMC Med, 2022, 20(1): 142. DOI: 10.1186/s12916-022-02346-9. doi: 10.1186/s12916-022-02346-9
[19]	Miglietta F, Griguolo G, Bottosso M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer[J]. NPJ Breast Cancer, 2021, 7(1): 137. DOI: 10.1038/s41523-021-00343-4. doi: 10.1038/s41523-021-00343-4 pmid: 34642348
[20]	Tarantino P, Gandini S, Nicolò E, et al. Evolution of low HER2 expression between early and advanced-stage breast cancer[J]. Eur J Cancer, 2022, 163: 35-43. DOI: 10.1016/j.ejca.2021.12.022. doi: 10.1016/j.ejca.2021.12.022 pmid: 35032815
[21]	Miglietta F, Griguolo G, Bottosso M, et al. HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment[J]. NPJ Breast Cancer, 2022, 8(1): 66. DOI: 10.1038/s41523-022-00434-w. doi: 10.1038/s41523-022-00434-w pmid: 35595761
[22]	Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG oncology phase Ⅲ randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2[J]. J Clin Oncol, 2020, 38(5): 444-453. DOI: 10.1200/JCO.19.01455. doi: 10.1200/JCO.19.01455 pmid: 31821109
[23]	Corti C, Giugliano F, Nicolò E, et al. Antibody-drug conjugates for the treatment of breast cancer[J]. Cancers (Basel), 2021, 13(12): 2898. DOI: 10.3390/cancers13122898. doi: 10.3390/cancers13122898
[24]	Manich CS, O'shaughnessy J, Aftimos PG, et al. LBA15 primary outcome of the phase Ⅲ SYD985.002/TULIP trial comparing [vic-] trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer[J]. Ann Oncol, 2021, 32: S1288. DOI: 10.1016/j.annonc.2021.08.2088. doi: 10.1016/j.annonc.2021.08.2088
[25]	Banerji U, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study[J]. Lancet Oncol, 2019, 20(8): 1124-1135. DOI: 10.1016/S1470-2045(19)30328-6. doi: S1470-2045(19)30328-6 pmid: 31257177
[26]	Perez J, Garrigós L, Gion M, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond[J]. Expert Opin Biol Ther, 2021, 21(7): 811-824. DOI: 10.1080/14712598.2021.1890710. doi: 10.1080/14712598.2021.1890710 pmid: 33759669
[27]	Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20. DOI: 10.1056/NEJMoa2203690. doi: 10.1056/NEJMoa2203690
[28]	Barroso-Sousa R, Tolaney SM. Clinical development of new antibody-drug conjugates in breast cancer: to infinity and beyond[J]. BioDrugs, 2021, 35(2): 159-174. DOI: 10.1007/s40259-021-00472-z. doi: 10.1007/s40259-021-00472-z pmid: 33666903
[29]	Eiger D, Agostinetto E, Saúde-Conde R, et al. The exciting new field of HER2-low breast cancer treatment[J]. Cancers (Basel), 2021, 13(5): 1015. DOI: 10.3390/cancers13051015. doi: 10.3390/cancers13051015
[30]	Won HS, Ahn J, Kim Y, et al. Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society[J]. Breast Cancer Res, 2022, 24(1): 22. DOI: 10.1186/s13058-022-01519-x. doi: 10.1186/s13058-022-01519-x pmid: 35307014
[31]	Tan RSYC, Ong WS, Lee KH, et al. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis[J]. BMC Med, 2022, 20(1): 105. DOI: 10.1186/s12916-022-02284-6. doi: 10.1186/s12916-022-02284-6 pmid: 35296300
[32]	Hein A, Hartkopf AD, Emons J, et al. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status[J]. Eur J Cancer, 2021, 155: 1-12. DOI: 10.1016/j.ejca.2021.06.033. doi: 10.1016/j.ejca.2021.06.033 pmid: 34311211
[33]	Gampenrieder SP, Rinnerthaler G, Tinchon C, et al. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry[J]. Breast Cancer Res, 2021, 23(1): 112. DOI: 10.1186/s13058-021-01492-x. doi: 10.1186/s13058-021-01492-x pmid: 34906198
[34]	Li Y, Abudureheiyimu N, Mo H, et al. In real life, low-level HER2 expression may be associated with better outcome in HER2-negative breast cancer: a study of the National Cancer Center, China[J]. Front Oncol, 2022, 11: 774577. DOI: 10.3389/fonc.2021.774577. doi: 10.3389/fonc.2021.774577